title: Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer.
abstract: The purpose of this study was to determine the response in patients with recurrent, chemotherapy-resistant ovarian cancer to a combination of the LHRH-analog goserelin and tamoxifen.
  
  
  METHODS
  Twenty-five patients with recurrent, chemotherapy resistant ovarian cancer received a combination of goserelin and tamoxifen until clinical or serological evidence of progression as measured by serum CA-125 levels. Suppression of LH, FSH and prolactin levels in this group were compared with a second group of ten patients treated with decapeptyl for the same indication.
  
  
  RESULTS
  The combination was well tolerated. The median progression free survival amounted to five (range 2-96+) months and overall survival to eight (range 3-96+) months. One of the responding patients is still alive without progression at 8 years. With this combination the median levels of LH and FSH were markedly suppressed, to respectively 2.6% and 3.7% of baseline values. With decapeptyl the LH levels were also suppressed, but the resulting FSH levels were significantly higher. PA combination of goserelin and tamoxifen in patients with relapsed ovarian cancer can not be recommended as standard therapy, but may result in long-term survival in individual patients.
authors.affiliation: Department of Medical Oncology, University Hospital Groningen, The Netherlands.
authors.forename: L S
authors.initials: LS
authors.lastname: Hofstra
authors.forename: M J
authors.initials: MJ
authors.lastname: Mourits
authors.forename: E G
authors.initials: EG
authors.lastname: de Vries
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage*
chemical_list: D018394:CA-125 Antigen; D013629:Tamoxifen; D017273:Goserelin; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone